canakinumab
Novartis
[]
garon: presenting canopy trial. no benefit for use of canakinab in adjuvant setting. not really surprised given the science underlying this study. #esmo22
Medical Oncologist, Translational Researcher, Peter Mac. Tweets are my own opinions. Musician (@mayhemtomi) https://t.co/f3ccD2Ml7v